07:00 , May 18, 2015 |  BC Week In Review  |  Clinical News

PA-824: Phase III started

Not-for-profit TB Alliance began the open-label, South African Phase III Nix-TB trial to evaluate the all-oral regimen of PA-824, Sirturo bedaquiline and Zyvox linezolid in about 200 patients ages >=14. Patients will receive 400 mg...
08:00 , Jan 10, 2011 |  BioCentury  |  Finance

Buyside View XIX: Commercial Risk

Michael Flanagan Senior Writer  BioCentury's 19th Annual Buyside View finds money managers entering 2011 cautiously optimistic about biotech's prospects, particularly as some of the high-profile compounds have already reported some data, lowering risk. Amidst the...
07:00 , Oct 28, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes BCL2/adenovirus E1B 19kDa interacting protein 3-like (BNIP3L; NIX) Studies in mice suggest that inhibiting NIX could help treat diabetes. In a mouse model...
07:00 , Aug 2, 2010 |  BioCentury  |  Finance

Shareholders swamp river

Even though it will cost $30 million in cash, shareholders of Charles River Laboratories International Inc. (NYSE:CRL) got their wish last week when the company succumbed to their opposition to the planned acquisition of fellow...
07:00 , Mar 20, 2008 |  BC Innovations  |  Markers

Micro Management

In the past four years, at least two biotechs have released tests that use mRNA-based gene signatures to predict the likelihood of breast cancer recurrence. Now, research is emerging that suggests microRNAs could also have...
07:00 , Apr 19, 1999 |  BioCentury  |  Politics, Policy & Law

Austria rebuffs olive branch

OXFORD - Austria's government has rejected an olive branch from a consortium of seed companies and the food industry. Officials at the Ministries of Agriculture and Consumer Affairs have turned down an opportunity to conduct...